Tags

Type your tag names separated by a space and hit enter

Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform.
PLoS One. 2021; 16(6):e0252628.Plos

Abstract

Serological assessment of SARS-CoV-2 specific responses are an essential tool for determining the prevalence of past SARS-CoV-2 infections in the population especially when testing occurs after symptoms have developed and limited contact tracing is in place. The goal of our study was to test a new 10-plex electro-chemiluminescence-based assay to measure IgM and IgG responses to the spike proteins from multiple human coronaviruses including SARS-CoV-2, assess the epitope specificity of the SARS-CoV-2 antibody response against full-length spike protein, receptor-binding domain and N-terminal domain of the spike protein, and the nucleocapsid protein. We carried out the assay on samples collected from three sample groups: subjects diagnosed with COVID-19 from the U.S. Army hospital at Camp Humphreys in Pyeongtaek, South Korea; healthcare administrators from the same hospital but with no reported diagnosis of COVID-19; and pre-pandemic samples. We found that the new CoV-specific multiplex assay was highly sensitive allowing plasma samples to be diluted 1:30,000 with a robust signal. The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples. The data from the three sample groups also revealed a unique pattern of cross-reactivity between SARS-CoV-2 and SARS-CoV-1, MERS-CoV, and seasonal coronaviruses HKU1 and OC43. Our findings show that the CoV-2 IgM response is highly specific while the CoV-2 IgG response is more cross-reactive across a range of human CoVs and also showed that IgM and IgG responses show distinct patterns of epitope specificity. In summary, this multiplex assay was able to distinguish samples by COVID-19 status and characterize distinct trends in terms of cross-reactivity and fine-specificity in antibody responses, underscoring its potential value in diagnostic or serosurveillance efforts.

Authors+Show Affiliations

Center Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.Clinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.Immunology Core, Malaria Biologics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America. Henry M. Jackson Foundation for The Advancement of Military Medicine, Bethesda, MD, United States of America.Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.Brian D. Allgood Army Community Hospital, Camp Humphreys, Pyeongtaek, South Korea.Brian D. Allgood Army Community Hospital, Camp Humphreys, Pyeongtaek, South Korea.Brian D. Allgood Army Community Hospital, Camp Humphreys, Pyeongtaek, South Korea.Brian D. Allgood Army Community Hospital, Camp Humphreys, Pyeongtaek, South Korea.Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.Henry M. Jackson Foundation for The Advancement of Military Medicine, Bethesda, MD, United States of America.Immunology Core, Malaria Biologics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.United States Forces Korea Surgeon, Camp Humphreys, South Korea.Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.Immunology Core, Malaria Biologics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

34081747

Citation

Chaudhury, Sidhartha, et al. "Serological Profiles of Pan-coronavirus-specific Responses in COVID-19 Patients Using a Multiplexed Electro-chemiluminescence-based Testing Platform." PloS One, vol. 16, no. 6, 2021, pp. e0252628.
Chaudhury S, Hutter J, Bolton JS, et al. Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. PLoS One. 2021;16(6):e0252628.
Chaudhury, S., Hutter, J., Bolton, J. S., Hakre, S., Mose, E., Wooten, A., O'Connell, W., Hudak, J., Krebs, S. J., Darden, J. M., Regules, J. A., Murray, C. K., Modjarrad, K., Scott, P., Peel, S., & Bergmann-Leitner, E. S. (2021). Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. PloS One, 16(6), e0252628. https://doi.org/10.1371/journal.pone.0252628
Chaudhury S, et al. Serological Profiles of Pan-coronavirus-specific Responses in COVID-19 Patients Using a Multiplexed Electro-chemiluminescence-based Testing Platform. PLoS One. 2021;16(6):e0252628. PubMed PMID: 34081747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. AU - Chaudhury,Sidhartha, AU - Hutter,Jack, AU - Bolton,Jessica S, AU - Hakre,Shilpa, AU - Mose,Evelyn, AU - Wooten,Amy, AU - O'Connell,William, AU - Hudak,Joseph, AU - Krebs,Shelly J, AU - Darden,Janice M, AU - Regules,Jason A, AU - Murray,Clinton K, AU - Modjarrad,Kayvon, AU - Scott,Paul, AU - Peel,Sheila, AU - Bergmann-Leitner,Elke S, Y1 - 2021/06/03/ PY - 2021/01/06/received PY - 2021/05/19/accepted PY - 2021/6/3/entrez PY - 2021/6/4/pubmed PY - 2021/6/4/medline SP - e0252628 EP - e0252628 JF - PloS one JO - PLoS One VL - 16 IS - 6 N2 - Serological assessment of SARS-CoV-2 specific responses are an essential tool for determining the prevalence of past SARS-CoV-2 infections in the population especially when testing occurs after symptoms have developed and limited contact tracing is in place. The goal of our study was to test a new 10-plex electro-chemiluminescence-based assay to measure IgM and IgG responses to the spike proteins from multiple human coronaviruses including SARS-CoV-2, assess the epitope specificity of the SARS-CoV-2 antibody response against full-length spike protein, receptor-binding domain and N-terminal domain of the spike protein, and the nucleocapsid protein. We carried out the assay on samples collected from three sample groups: subjects diagnosed with COVID-19 from the U.S. Army hospital at Camp Humphreys in Pyeongtaek, South Korea; healthcare administrators from the same hospital but with no reported diagnosis of COVID-19; and pre-pandemic samples. We found that the new CoV-specific multiplex assay was highly sensitive allowing plasma samples to be diluted 1:30,000 with a robust signal. The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples. The data from the three sample groups also revealed a unique pattern of cross-reactivity between SARS-CoV-2 and SARS-CoV-1, MERS-CoV, and seasonal coronaviruses HKU1 and OC43. Our findings show that the CoV-2 IgM response is highly specific while the CoV-2 IgG response is more cross-reactive across a range of human CoVs and also showed that IgM and IgG responses show distinct patterns of epitope specificity. In summary, this multiplex assay was able to distinguish samples by COVID-19 status and characterize distinct trends in terms of cross-reactivity and fine-specificity in antibody responses, underscoring its potential value in diagnostic or serosurveillance efforts. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/34081747/Serological_profiles_of_pan_coronavirus_specific_responses_in_COVID_19_patients_using_a_multiplexed_electro_chemiluminescence_based_testing_platform_ L2 - https://dx.plos.org/10.1371/journal.pone.0252628 DB - PRIME DP - Unbound Medicine ER -